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Girl, 2½ years, chest embryonal rhabdomyosarcoma operated, followed by chemotherapy, 6 cycles of VAT. After the chemotherapy
she developed a fast growing local recurrence involving the pericardium and great vessels. Tumor Board decided treatment with
preoperative radiotherapy and chemotherapy followed by radical surgery and intraoperative radiotherapy. After radiochemother-
apy treatment, the patient achieved a partial response. For virtual simulation prior to surgery and dosimetric preplanning of
overprinting with intraoperative radiotherapy to the surgical bed, we have been used a simulator developed in Spain through
the collaboration of several Health Centers, Universities and private industry. We shown surgical and radiotherapy procedures,
results and tolerance.
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Intraoperative radiotherapy (IORT) may be deﬁned as a form of radiotherapy based on the administration, during surgery, a
high single dose of radiation on a surgical bed or unresectable tumor, while separating surrounding healthy tissues from the
beam radiation. This is ultimately a high precision technique dosimetric quality (homogeneity in the dose) for intensifying
the treatment. The IORT has been used in the management of unresectable tumors, tumors resectable residual disease and,
in combination with chemoradiation and chemotherapy in tumors with a high risk of local recurrence. Conducting IORT tech-
niques require the availability of a multidisciplinary team coordinated and adequately trained and hospital unit with accurate
infrastructure and equipment. The advantages can be summarized as: (1) Convenience: IORT allows both surgery and radiation
therapy are completed in a single therapeutic act. So it disaappears risks associated with lack of compliance with an entire
conventional radiotherapy and prolonged delays associated treatments such as hormone therapy and chemotherapy. (2) Biolog-
ical efﬁcacy: IORT allows the radiation dose to be applied directly to the surgical margins which eliminates the risk of residual
tumor geographical loss. (3) Safety: IORT allows the surgeon and radiation oncologist minimize exposure of healthy tissue to
radiation which results in a clear reduction in the risk of toxicity. (4) Cost: IORT allows management of the entire radiotherapy
treatment in a single dose which is a clear decrease in time compared to conventional treatment (1 day versus 6–7 weeks). The
continuing advances in applications, technology and methodology of Radiation Oncology has raised the level of complexity of
this specialty. IORT has not been immune to this process and provides an excellent platform for innovation and research in the
multidisciplinary management of cancer.
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